Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients

N/ANot Yet RecruitingNCT06101914

Power Life Sciences Inc.500 enrolled

Overview

Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Treatment Resistant Depression

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of treatment resistant depression * Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * No prior treatment for treatment resistant depression Exclusion Criteria: * Enrolled in another research study * Inability to provide written informed consent * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Locations (1)

Power Life Sciences

San Francisco, California, United States

Outcomes

Primary Outcomes

Rate of patients who decide to enroll in a treatment resistant depression clinical research.

Time frame: 3 months

Number of treatment resistant depression study participants who remain in clinical study until completion.

Time frame: 12 months

Central Contacts

Michael B Gill

CONTACT

4159004227 bask@withpower.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.